abstract：:The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy deci...

journal_title：PharmacoEconomics

authors： Greenberg PE,Arcelus A,Birnbaum HG,Cremieux PY,LeLorier J,Ouellette P,Slavin MB

更新日期：1999-11-01 00:00:00

abstract：OBJECTIVE:To compare the cost effectiveness of sequential intravenous (i.v.) to oral ciprofloxacin plus metronidazole (CIP/MTZ i.v./PO) with that of i.v. ciprofloxacin plus i.v. metronidazole (CIP/MTZ i.v.) and i.v. imipenem-cilastatin (IMI i.v.) in patients with intra-abdominal infections. DESIGN AND PARTICIPANTS:Pat...

journal_title：PharmacoEconomics

authors： Walters DJ,Solomkin JS,Paladino JA

更新日期：1999-11-01 00:00:00

abstract：OBJECTIVE:To develop incidence-based estimates of the cost of several diabetes-related complications. DESIGN AND SETTING:This was a retrospective cohort study in a large health maintenance organisation. A total of 8905 patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus and 36...

journal_title：PharmacoEconomics

authors： Ramsey SD,Newton K,Blough D,McCulloch DK,Sandhu N,Wagner EH

更新日期：1999-09-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. DESIGN AND SETTING:An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cos...

journal_title：PharmacoEconomics

authors： Morris S,Godber E

更新日期：1999-08-01 00:00:00

abstract：OBJECTIVE:The aim of the present study is to describe a refinement of a previously presented method, based on the concept of point sensitivity, to deal with uncertainty in economic studies. DESIGN:The original method was refined by the incorporation of probability distributions which allow a more accurate assessment o...

journal_title：PharmacoEconomics

authors： Nuijten MJ

更新日期：1999-07-01 00:00:00

abstract：OBJECTIVE:Our objective was to identify, among the information routinely collected on patients in intensive care units (ICUs), data that determine the total cost for a given patient. DESIGN:We developed a model that could help physicians in medical ICUs to estimate the cost of care for their patients when no cost data...

journal_title：PharmacoEconomics

authors： Chaix C,Durand-Zaleski I,Alberti C,Brun-Buisson C

更新日期：1999-06-01 00:00:00

abstract：:Pharmacoeconomic data may be obtained within the context of randomised clinical trials (RCTs) and from effectiveness studies in the 'real world'. The differences between the 2 types of study design have implications for the types of data that can be obtained and the interpretation of the resulting findings. Because RC...

journal_title：PharmacoEconomics

authors： Revicki DA,Frank L

更新日期：1999-05-01 00:00:00

abstract：:Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful measurements of complianc...

journal_title：PharmacoEconomics

authors： Urquhart J

更新日期：1999-03-01 00:00:00

abstract：:Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups of patients. Both direc...

journal_title：PharmacoEconomics

authors： Jønsson V,Hansen MM,Ljungman P,Kaasa S

更新日期：1999-02-01 00:00:00

abstract：BACKGROUND:Healthcare resource use data were collected for 1 year as part of the CAESAR (Canada, Australia, Europe, South Africa) clinical trial, which evaluated the effect of adding lamivudine to treatment regimens containing zidovudine in patients with HIV infection. This study showed that lamivudine-containing regim...

journal_title：PharmacoEconomics

authors： Lacey L,Mauskopf J,Lindrooth R,Pham S,Saag M,Sawyer W

更新日期：1999-01-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to develop a generic treatment algorithm for influenza and influenza-like illness (ILI) that could be used to estimate the costs and outcomes of current and new treatments for influenza in different countries for different patient subgroups. METHODS:A series of possible treatment pa...

journal_title：PharmacoEconomics

authors： Mauskopf JA,Cates SC,Griffin AD

更新日期：1999-01-01 00:00:00

abstract：OBJECTIVE:Patients with cancer-associated neutropenia are at high risk of developing severe infections which can be fatal if treatment is not promptly administered. For this reason, fever is treated as soon as possible with broad spectrum antibacterial therapy. The objective of this study was to conduct a cost analysis...

journal_title：PharmacoEconomics

authors： Bucaneve G,Menichetti F,Del Favero A

更新日期：1999-01-01 00:00:00

abstract：UNLABELLED:Cyclosporin microemulsion (Neoral) is a self-emulsifying preconcentrate of cyclosporin which is more rapidly and consistently absorbed than the original oil-based formulation of cyclosporin (standard formulation; Sandimmun, Sandimmune). This superior pharmacokinetic profile suggests that cyclosporin microemu...

journal_title：PharmacoEconomics

authors： Coukell AJ,Plosker GL

更新日期：1998-12-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

journal_title：PharmacoEconomics

authors： Nuijten M,Hadjadjeba L,Evans C,van den Berg J

更新日期：1998-10-01 00:00:00

abstract：OBJECTIVE:The aim of the study was to determine the costs and effects associated with a community pharmacy-based smoking-cessation programme in Northern Ireland, using the perspective of the payer in the main analysis. DESIGN AND SETTING:Data from a pilot study conducted in 2 community pharmacies in Northern Ireland w...

journal_title：PharmacoEconomics

authors： Crealey GE,McElnay JC,Maguire TA,O'Neill C

更新日期：1998-09-01 00:00:00

abstract：OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

journal_title：PharmacoEconomics

authors： Pibernik-Okanović M,Szabo S,Metelko Z

更新日期：1998-08-01 00:00:00

abstract：:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component...

journal_title：PharmacoEconomics

authors： Chang K,Nash D

更新日期：1998-07-01 00:00:00

abstract：:This century has seen a phenomenal growth in the development, understanding and use of pharmaceuticals. Additionally, this period has seen the balance of the treatment needs of patients shift dramatically from infectious to cardiovascular and cancer diseases, and from infancy and middle-age to old age. The value of mo...

journal_title：PharmacoEconomics

authors： Mason J,Freemantle N

更新日期：1998-06-01 00:00:00

abstract：:Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Phillips P,Rotstein C,Puodziunas A,Shafran S,Garber G,Smaill F,Salit I,Miller M,Williams K,Conly J,Singer J,Ioannou S

更新日期：1998-05-01 00:00:00

abstract：:This willingness-to-pay (WTP) analysis is the first study of its kind undertaken in Australia to support an application for listing of a new drug on the Australian national formulary. The technique offers the advantage of being able to summarise diverse outcomes of therapy in a single unit of measure. Willingness to p...

journal_title：PharmacoEconomics

authors： Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Dobson M

更新日期：1998-03-01 00:00:00

abstract：:Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

journal_title：PharmacoEconomics

authors： Gupta AK

更新日期：1998-02-01 00:00:00

abstract：:Cefotaxime is a parenterally administered third generation cephalosporin with a broad spectrum of antimicrobial activity. After more than a decade of use, cefotaxime continues to play an important role in the treatment of patients with serious infections, particularly those caused by Gram-negative bacteria. Clinical t...

journal_title：PharmacoEconomics

authors： Plosker GL,Foster RH,Benfield P

更新日期：1998-01-01 00:00:00

abstract：:Health economic models for identifying therapeutic options that maximise health benefits from limited healthcare resources are being developed in a number of therapeutic areas. The development of such a model for upper gastrointestinal (UGI) symptoms to support decision-making by primary care clinicians is of particul...

journal_title：PharmacoEconomics

authors： Haycox A,Butterworth M,Walley T,Barton S

更新日期：1998-01-01 00:00:00

abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

journal_title：PharmacoEconomics

authors： Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

更新日期：1997-12-01 00:00:00

abstract：:The elderly are a heterogeneous population group who range from well and completely independent individuals to a smaller proportion who are frail, require help and are high users of the healthcare system. Since health is a state of well-being which includes the domains of social, spiritual, psychological and physical ...

journal_title：PharmacoEconomics

authors： Turpie I,Strang D,Darzins P,Guyatt G

更新日期：1997-11-01 00:00:00

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：:This study examined the costs of treatment of, and quality of life in, patients with antineoplastic therapy-induced neutropenic fever who were treated with antibacterials, with or without granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients with haematological malignancies (n = 47) or solid tumours (n =...

journal_title：PharmacoEconomics

authors： Uyl-de Groot CA,Vellenga E,de Vries EG,Löwenberg B,Stoter GJ,Rutten FF

更新日期：1997-09-01 00:00:00

abstract：:Recent studies have shown that ACE inhibitors reduce morbidity and mortality after myocardial infarction (MI). While these trials have obvious clinical implications, the widespread introduction of a new treatment for a condition as common as MI also has clear cost implications. The results of the post-MI studies with ...

journal_title：PharmacoEconomics

authors： Hummel S,Piercy J,Wright R,Davie A,Bagust A,McMurray J

更新日期：1997-08-01 00:00:00

abstract：:We estimated the cost effectiveness of adding the ACE inhibitor ramipril to conventional treatment in patients with heart failure after acute myocardial infarction. These estimates were based on the Acute Infarction Ramipril Efficacy (AIRE) study and on complementary Swedish healthcare resource use data for a subset o...

journal_title：PharmacoEconomics

authors： Erhardt L,Ball S,Andersson F,Bergentoft P,Martinez C

更新日期：1997-08-01 00:00:00

abstract：:This study evaluated the cost utility of adding interferon-alpha 2b to conventional treatment in patients with multiple myeloma. It also provides a methodology for transforming complex quality-of-life profiles into a single index value on the conventional 0 to 1 quality-adjusted life-year scale (QALY). From 1990 to 19...

journal_title：PharmacoEconomics

authors： Nord E,Wisløff F,Hjorth M,Westin J

更新日期：1997-07-01 00:00:00

abstract：:Several randomised comparative trials have shown that granulocyte colony-stimulating factor (G-CSF) reduces the duration of neutropenia, hospitalisation and intravenous antibacterial use in patients with cancer who are receiving high-dosage antineoplastic therapy. However, one area that has received less attention is ...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Altmayer C,Quirt I

更新日期：1997-06-01 00:00:00

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：:This study evaluated the cost of sequential treatment with once-daily ofloxacin or twice-daily ciprofloxacin in 474 hospitalised patients in different countries. The patients were treated intravenously for at least 3 days, then orally for 7 to 10 days or for 3 days beyond the disappearance of infection-related symptom...

journal_title：PharmacoEconomics

authors： Salewski E,Bassaris HP,Calangu S,Kitzes R,Kosmidis J,Raz R,Kompan L

更新日期：1997-04-01 00:00:00

abstract：:The recent licensing of interferon-beta for use in patients with multiple sclerosis has caused concern, in view of the equivocal evidence of efficacy, pressure of public expectation towards its use and the high expected cost if widespread use were to be sanctioned. Whether such alarm is justified remains a moot point....

journal_title：PharmacoEconomics

authors： Tolley KH,Whynes DK

更新日期：1997-03-01 00:00:00

abstract：:The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...

journal_title：PharmacoEconomics

authors： Dahlöf C,Bouchard J,Cortelli P,Heywood J,Jansen JP,Pham S,Hirsch J,Adams J,Miller DW

更新日期：1997-01-01 00:00:00

abstract：:An increasing number of ACE inhibitors have become available in recent years. Because these agents are all similar, careful scrutiny is required in order to determine specific advantages of particular agents when making formulary decisions. Differences between agents with regard to structure and tissue specificity hav...

journal_title：PharmacoEconomics

authors： Gerbrandt KR,Yedinak KC

更新日期：1996-12-01 00:00:00

abstract：:The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

journal_title：PharmacoEconomics

authors： Brecht JG,Poldrugo F,Schädlich PK

更新日期：1996-11-01 00:00:00

abstract：:This study was designed to compare the costs of a pharmacy-based Central Intravenous Additive Service (CIVAS) with those of traditional ward-based preparation of intravenous doses for a paediatric population. Labour costs were derived from timings of preparation of individual doses in both the pharmacy and ward by an ...

journal_title：PharmacoEconomics

authors： Armour DJ,Cairns CJ,Costello I,Riley SJ,Davies EG

更新日期：1996-10-01 00:00:00

abstract：:Since the inception of the National Health Service in 1948, successive British governments have taken various measures to restrain the growth of the medicines bill. A total of 10 different measures have been introduced with very limited success. The most effective measures have been those directed at increasing the le...

journal_title：PharmacoEconomics

authors： Griffin JP

更新日期：1996-09-01 00:00:00

abstract：:Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

journal_title：PharmacoEconomics

authors： Dunn CJ,Goa KL

更新日期：1996-08-01 00:00:00